Observational Study of TEG Indices in Cancer Patients Undergoing Surgery
This study is looking at how blood clotting measurements, called TEG indices (thromboelastography), relate to different cancers like liver, esophageal, colorectal, and lung adenocarcinoma. Researchers want to see if these TEG indices can help predict how severe the cancer is, if it will come back, how long people live, and if there will be bleeding or clotting problems after surgery. You may be able to join if you are 18 or older and have a new diagnosis of one of these cancers. The study is also looking at healthy individuals as a control group. The main goals are to see how TEG indices connect to the cancer's stage, and to identify potential complications before and after surgery. The current recruitment status is unclear.
- Study design
- This is an observational study planning to enroll 400 participants. It is not specified if it is randomized or blinded.
- What's involved
- Participants will provide blood samples for TEG indices. The specific number of visits or duration of participation is not detailed.
- Compensation
- Not stated in the trial record.
- Follow-up
- TEG indices, disease burden, and pre-operative complications will be measured at one year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Ana Gleisner, MD · PRINCIPAL_INVESTIGATOR · University of Colorado, Denver
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- TEG indices of coagulationOne Year
R time (minutes \~ coagulation factors), angle (degrees \~ fibrinogen function), MA (mm \~ platelets function), and LY30 (%\~ fibrinolysis) measured at baseline (initial presentation or time of diagnosis), after neoadjuvant chemotherapy (if applicable), pre-operatively (before the induction of general anesthesia), intra-operatively (after tumor removal), post-operative days 1, 3 and 5, and at routine follow up appointments at 2 weeks, 3 months, 6 months and 1 year after surgery.
- Disease burden as measured by TNM stagingOne year
Disease burden as measured by TNM staging
- Pre- operative thrombotic and hemorrhagic complications.One Year
Pre-operative thrombotic and hemorrhagic complications.
- Recurrence free and overall survival.One Year
Recurrence free and overall survival.
- Proteomic analysis of intro-operative sample tumor microenvironmentOne Year
Proteomic analysis of intro-operative sample tumor microenvironment
- Post-operative thrombotic and hemorrhagic complicationsOne Year
Post-operative thrombotic and hemorrhagic complications